+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients



Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients



Transplantation Proceedings 25(4): 2574




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045589687

Download citation: RISBibTeXText

PMID: 8356675


Related references

A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transplant International 11(3): 231-236, 1998

Low-dose OKT3 with mycophenolate versus standard-dose OKT3 without mycophenolate induction in high risk kidney transplant recipients. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 664A, 1998

Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients. Transplantation Proceedings 28(6): 3466-3467, 1996

Comparison between methylprednisolone and OKT3 treatment for the first acute rejection episode in combined kidney and pancreas transplant recipients. Transplantation Proceedings 27(6): 3133-3134, 1995

Modulation of peripheral blood T-lymphocytes in kidney transplant recipients treated with low dose OKT3 therapy. Immunology Letters 91(1): 75-77, 2004

Single-Dose Regimen Of Daclizumab Is As Effective As Two-Dose Regimen For Prevention Of Acute Rejection In Chinese Kidney Transplant Recipients. Transplantation 82(Suppl 2): 507-508, 2006

A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation 69(11): 2374-2381, 2000

Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients. Transplantation Proceedings 30(2): 285-287, 1998

Pentoxifylline does not prevent cytokine induced first dose reactions following therapy of acute renal transplant rejection with OKT3. Nephrology Dialysis Transplantation 10(6): 1070, 1995

Randomized prospective study comparing low-dose OKT3 of low-dose antithymocyte globulins for treatment of the first acute rejection of kidney allografts. Nephrology Dialysis Transplantation 11(6): A276, 1996

Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. Pediatric Transplantation 12(1): 32-39, 2008

OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection. Journal of Pediatrics 111(1): 45-50, 1987

High or low dose steroid therapy for acute renal transplant rejection after prophylactic Okt3 treatment: a prospective randomized study. Transplant International 5: S437-S439, 1992

High or low dose steroid therapy for acute renal transplant rejection after prophylactic OKT3 treatment: a prospective randomized study. Transplant International 5(Suppl. 1): S437-S439, 1992

The pharmacokinetic profile of standard and low-dose OKT3 induction immunosuppression in renal transplant recipients. Transplantation 58(2): 249-253, 1994